Cancer biomarkers in blood tests
Pro Research Analysisby 
Searched over 200M research papers
Blood-Based Cancer Biomarkers: Types and Clinical Relevance
Blood-based biomarkers, often referred to as "liquid biopsies," are emerging as powerful tools for cancer detection, diagnosis, prognosis, and treatment monitoring. These biomarkers offer a non-invasive, accessible, and cost-effective alternative to traditional tissue biopsies, which can be invasive, risky, and sometimes not feasible due to tumor location or patient condition Mamdani2017Yörüker2016Tsai2024.
Protein Biomarkers in Blood Tests for Cancer
Proteins such as tumor-associated antigens, autoantibodies, and exosomal proteins are among the most extensively studied blood-based biomarkers. These proteins can be detected in serum or plasma and have shown promise for early cancer detection, supplementing imaging-based screening methods, and monitoring treatment response and prognosis, especially in lung and breast cancers Fahrmann2022Huang2022Loke2018+1 MORE. For example, panels combining multiple protein markers have improved the sensitivity and specificity of lung cancer risk assessment compared to standard screening criteria .
Circulating Tumor DNA (ctDNA) and Genetic Biomarkers
Circulating tumor DNA (ctDNA) consists of small fragments of DNA shed by tumors into the bloodstream. ctDNA analysis allows for the detection of tumor-specific genetic and epigenetic alterations, providing a non-invasive means for early cancer diagnosis, monitoring disease progression, and guiding personalized treatment decisions. While ctDNA holds great promise, further validation is needed before it becomes a routine clinical tool Mamdani2017Yörüker2016Han2017+2 MORE.
MicroRNAs (miRNAs) and Long Noncoding RNAs (lncRNAs) as Blood Biomarkers
Cell-free microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) are stable in blood and resistant to degradation, making them attractive candidates for non-invasive cancer biomarkers. Altered levels of specific miRNAs and lncRNAs have been observed in various cancer types, and these molecules may also play roles in cancer development and progression. Their stability and ease of sampling make them promising for early detection and monitoring, though more research is needed to standardize their clinical use Ortiz-Quintero2016Loke2018Badowski2022+1 MORE.
Circulating Tumor Cells (CTCs) and Other Blood Components
Circulating tumor cells (CTCs), tumor-derived exosomes, and tumor-educated platelets (TEPs) are additional blood-based biomarkers under investigation. These components can provide real-time information about tumor biology, help in early detection, and offer insights into treatment resistance and disease recurrence Mamdani2017Yörüker2016Tsai2024+1 MORE.
Advantages and Challenges of Blood-Based Cancer Biomarkers
Blood-based biomarkers offer several advantages, including minimal invasiveness, ease of repeat sampling, and the potential for real-time monitoring of disease status. They can improve patient convenience, reduce healthcare costs, and enable earlier diagnosis, which is critical for improving cancer outcomes Mamdani2017Yörüker2016Tsai2024+2 MORE. However, challenges remain, such as the need for rigorous validation, standardization of assays, and addressing issues of sensitivity and specificity before these biomarkers can be widely adopted in clinical practice Fahrmann2022Huang2022Loke2018+1 MORE.
Conclusion
Blood-based cancer biomarkers—including proteins, ctDNA, miRNAs, lncRNAs, and CTCs—are transforming cancer detection and management by providing non-invasive, accessible, and dynamic tools for diagnosis, prognosis, and treatment monitoring. While significant progress has been made, further research and validation are needed to fully realize their potential in routine clinical care Mamdani2017Ortiz-Quintero2016Fahrmann2022+7 MORE.
Sources and full results
Most relevant research papers on this topic